BACKGROUND Familial renal glucosuria (FRG) is characterized by persistent glucosuria in the presence of normal serum glucose concentrations, and the absence of other impairments of tubular function. Mutations in the sodium-glucose co-transporter 2 (SGLT2) gene (SLC5A2) are causative of FRG the long-term outcome of which is well know. In the search for potential new drug targets for SGLT2 inhibi...

The path from initial discovery to the realisation of SGLT2 inhibitors as a foundational therapy for chronic kidney disease and heart failure, irrespective diabetes status, has been circuitous serendipitous. In 1835, French chemists isolated naturally occurring non-selective SGLT1/2 inhibitor phlorizin apple tree bark, with subsequent experiments detailing its glycosuric properties.1 However, i...

Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, has been widely used in treatment of diabetic nephropathy (DN). Previous studies have shown that it both glucose-lowering effects and renoprotective functions DN. Tubulointerstitial fibrosis plays an important role the pathogenesis development progression Angiotensin‑converting enzyme (ACE2), major component renin-angiotensin sy...

The present work reports for the first time the construction of a transgenic mouse strain with specific expression of Cre recombinase in the kidney proximal tubule. A Cre/loxP strategy was developed using sglt2 promoter to drive Cre recombinase expression in transgenic mice. The mouse sglt2 5' region consisting of the first exon, the first intron, and part of the second exon was cloned upstream...

OBJECTIVE To examine the effect of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on the major components of renal glucose reabsorption (decreased maximum renal glucose reabsorptive capacity [TmG], increased splay, and reduced threshold), using the pancreatic/stepped hyperglycemic clamp (SHC) technique. RESEARCH DESIGN AND METHODS Subjects with type 2 diabetes (n=12) and m...

This study investigated the safety and efficacy of the sodium-glucose co-transporter-2 (SGLT2) inhibitor luseogliflozin with differing carbohydrate intakes in Japanese individuals with type 2 diabetes (T2D). Participants were randomly assigned to 3 carbohydrate-adjusted meals for 14 days (days 1-14; a high carbohydrate [HC; 55% total energy carbohydrate] and high glycaemic index [HGI] meal; an ...

Abstract. The present study aimed to investigate the dynamics of clinical and laboratory parameters serum Klotho protein level in patients with diabetic kidney disease using nephroprotective therapy combined an inhibitor sodium-glucose cotransporter 2 (SGLT2) dapagliflozin.
 Methods. A total 76 type nephropathy (DN) were examined this prospective study. Control group - 20 healthy subjects....

Background The efficacy of novel glucose-lowering drugs in treating non-alcoholic fatty liver disease (NAFLD) is unknown. Aim To evaluate the dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter 2 (SGLT2) inhibitors NAFLD to perform a comparison between these treatments. Methods Electronic databases were systematicall...

Patients with type 2 diabetes are at high risk of developing renal and cardiovascular complications. Sodium–glucose cotransporter (SGLT2) inhibitors have garnered interest due to their glucose-independent cardiorenal protective effects, as reported in trials including participants without diabetes, such Dapagliflozin And Prevention Adverse outcomes Chronic Kidney Disease (DAPA-CKD) (1,2). These...